|
Compound class:
Synthetic organic
Comment: RTY-406 is an orally bioavailable dual ABCB4 (MDR3)/ABCB11 (BSEP) positive functional modulator. It targets core pathophysiological drivers of hepatobiliary disease, abnormal bile composition and reduced bile flow. Upregulating the transport functions of these proteins, rectifies these abnormalities, and intimates the application of RTY-406 as a disease modifying therapy for cholangitis/hepatobiliary indications.
|
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Garzel B, Yang H, Zhang L, Huang SM, Polli JE, Wang H. (2014)
The role of bile salt export pump gene repression in drug-induced cholestatic liver toxicity. Drug Metab Dispos, 42 (3): 318-22. [PMID:24335466] |
|
2. Hirschfield GM, Chapman RW, Karlsen TH, Lammert F, Lazaridis KN, Mason AL. (2013)
The genetics of complex cholestatic disorders. Gastroenterology, 144 (7): 1357-74. [PMID:23583734] |
|
3. Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls Jr CW, Lightfoot-Dunn R, Hamadeh HK. (2010)
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci, 118 (2): 485-500. [PMID:20829430] |
|
4. Oude Elferink RP, Paulusma CC. (2007)
Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Pflugers Arch, 453 (5): 601-10. [PMID:16622704] |
|
5. Stieger B. (2009)
Recent insights into the function and regulation of the bile salt export pump (ABCB11). Curr Opin Lipidol, 20 (3): 176-81. [PMID:19684528] |